Business people are weighing in on what the government should do to fix the likely economic hole post COVID, including suggesting tourism by rich people and selling desirable sections at $5 million each. While ‘Hey Big Spender’ made me feel good today, I’m not sure it’s the answer to potential economic woes.
Humans are pushmi-pullyus – we are physical individuals who exist in social structures. My worst fears of the post-pandemic world are how physical distancing may result in negative societal shifts.
Humans are more adaptable than they think they are. When travelling, wherever I am, what’s happening quickly starts to seem normal. This makes sense as living in a constant state of stress would be impossible. Will COVID start to feel normal soon?
I took a tour around closed-for-COVID Queenstown, normally a humming hub of tourism. Here is what I saw…
We are still holding our breaths but the Ardern & Bloomfield Show tomorrow will tell us whether we will be stepping down from Level 4. What do you pick? What do I pick? I’ve looked up the factors that are likely to be taken into account.
How will our COVID story be told long after the pandemic? Will we have saved people? Will we have ‘saved’ the economy? Noting this is not a necessary dichotomy – saving one or the other. We are now comfortable with a Level 4 lockdown but, at some point, the restrictions will have to loosen up.
COVID is boring. Last time I got bored with my situation, I took a ride across part of the United States. It was fun…Type 2 fun that is only fun in the recounting. It pays to be careful what one wishes for.
What can you do when there’s not much to do and you are feeling depressed about the COVID situation? Torture your cat!
Controlling rabbits has parallels with controlling COVID. It is hard and the subject of control expands at an exponential rate. Elimination appears attractive but is a challenging goal.
A musical representation of COVID-19 was made using a tone for each amino acid in its DNA sequence. Sequencing COVID’s DNA is the key to creating an effective vaccine. Vaccine development is moving at breakneck speed – Oxford University has approval for a first Clinical Trial in late April.
